Efficacy and safety of endostar® combined with chemotherapy in patients with advanced soft tissue sarcomas.

@article{Zhang2013EfficacyAS,
  title={Efficacy and safety of endostar® combined with chemotherapy in patients with advanced soft tissue sarcomas.},
  author={Lu-ping Zhang and Xing-yun Liao and Yan-mei Xu and Lv-Jun Yan and Gui-fang Yan and Xin-Xin Wang and Yu-zhong Duan and J Sun},
  journal={Asian Pacific journal of cancer prevention : APJCP},
  year={2013},
  volume={14 7},
  pages={
          4255-9
        }
}
BACKGROUND Soft tissue sarcomas (STS) are a heterogeneous group of tumors, and approximately 40-50% of patients with STS develop metastatic disease. The median overall survival of those patients was 12 months and their 5-year survival rate was 8%. Therefore, study on more effective treatment, especially the targeting therapies, is urgently needed. OBJECTIVE To evaluate the efficacy and safety of Endostar® combined with chemotherapy in patients with advanced STS. METHODS A retrospective case… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Gastrointestinal stromal tumors ( GIST ) : a rare entity , a tumor model for personalized therapy , and yet ten different molecular subtypes

  • JY Blay, CA Le, PA Cassier
  • Discov Med
  • 2012

Similar Papers

Loading similar papers…